These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 20729074)

  • 1. Bevacizumab/docetaxel association is more efficient than docetaxel alone in reducing breast and prostate cancer cell growth: a new paradigm for understanding the therapeutic effect of combined treatment.
    Ortholan C; Durivault J; Hannoun-Levi JM; Guyot M; Bourcier C; Ambrosetti D; Safe S; Pagès G
    Eur J Cancer; 2010 Nov; 46(16):3022-36. PubMed ID: 20729074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acceleration of clear cell renal cell carcinoma growth in mice following bevacizumab/Avastin treatment: the role of CXCL cytokines.
    Grepin R; Guyot M; Jacquin M; Durivault J; Chamorey E; Sudaka A; Serdjebi C; Lacarelle B; Scoazec JY; Negrier S; Simonnet H; Pages G
    Oncogene; 2012 Mar; 31(13):1683-94. PubMed ID: 21909141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of trastuzumab/docatexel combination on breast cancer angiogenesis: dichotomus effect predictable by the HIFI alpha/VEGF pre-treatment status?
    Koukourakis MI; Simopoulos C; Polychronidis A; Perente S; Botaitis S; Giatromanolaki A; Sivridis E
    Anticancer Res; 2003; 23(2C):1673-80. PubMed ID: 12820439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The potential of anti-vascular endothelial growth factor therapy in metastatic breast cancer: clinical experience with anti-angiogenic agents, focusing on bevacizumab.
    Marty M; Pivot X
    Eur J Cancer; 2008 May; 44(7):912-20. PubMed ID: 18396037
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and biological significance of vascular endothelial growth factor in endometrial cancer.
    Kamat AA; Merritt WM; Coffey D; Lin YG; Patel PR; Broaddus R; Nugent E; Han LY; Landen CN; Spannuth WA; Lu C; Coleman RL; Gershenson DM; Sood AK
    Clin Cancer Res; 2007 Dec; 13(24):7487-95. PubMed ID: 18094433
    [TBL] [Abstract][Full Text] [Related]  

  • 6. VEGF as a marker for outcome among advanced breast cancer patients receiving anti-VEGF therapy with bevacizumab and vinorelbine chemotherapy.
    Burstein HJ; Chen YH; Parker LM; Savoie J; Younger J; Kuter I; Ryan PD; Garber JE; Chen H; Campos SM; Shulman LN; Harris LN; Gelman R; Winer EP
    Clin Cancer Res; 2008 Dec; 14(23):7871-7. PubMed ID: 19047116
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bevacizumab in the treatment of metastatic breast cancer.
    Traina TA
    Oncology (Williston Park); 2009 Apr; 23(4):327-32. PubMed ID: 19476261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bevacizumab treatment of prostate cancer.
    Small AC; Oh WK
    Expert Opin Biol Ther; 2012 Sep; 12(9):1241-9. PubMed ID: 22775507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer.
    Miles DW; Chan A; Dirix LY; Cortés J; Pivot X; Tomczak P; Delozier T; Sohn JH; Provencher L; Puglisi F; Harbeck N; Steger GG; Schneeweiss A; Wardley AM; Chlistalla A; Romieu G
    J Clin Oncol; 2010 Jul; 28(20):3239-47. PubMed ID: 20498403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of yeast-derived beta-glucan in conjunction with bevacizumab for the treatment of human lung adenocarcinoma in subcutaneous and orthotopic xenograft models.
    Zhong W; Hansen R; Li B; Cai Y; Salvador C; Moore GD; Yan J
    J Immunother; 2009 Sep; 32(7):703-12. PubMed ID: 19561538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-vascular endothelial growth factor receptor-1 antagonist antibody as a therapeutic agent for cancer.
    Wu Y; Zhong Z; Huber J; Bassi R; Finnerty B; Corcoran E; Li H; Navarro E; Balderes P; Jimenez X; Koo H; Mangalampalli VR; Ludwig DL; Tonra JR; Hicklin DJ
    Clin Cancer Res; 2006 Nov; 12(21):6573-84. PubMed ID: 17085673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of RAD001 (everolimus) and docetaxel reduces prostate and breast cancer cell VEGF production and tumour vascularisation independently of sphingosine-kinase-1.
    Alshaker H; Wang Q; Böhler T; Mills R; Winkler M; Arafat T; Kawano Y; Pchejetski D
    Sci Rep; 2017 Jun; 7(1):3493. PubMed ID: 28615679
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-angiogenic effect of tamoxifen combined with epirubicin in breast cancer patients.
    Mele T; Generali D; Fox S; Brizzi MP; Bersiga A; Milani M; Allevi G; Bonardi S; Aguggini S; Volante M; Dogliotti L; Bottini A; Harris A; Berruti A
    Breast Cancer Res Treat; 2010 Oct; 123(3):795-804. PubMed ID: 20680681
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autocrine vascular endothelial growth factor signalling in breast cancer. Evidence from cell lines and primary breast cancer cultures in vitro.
    Weigand M; Hantel P; Kreienberg R; Waltenberger J
    Angiogenesis; 2005; 8(3):197-204. PubMed ID: 16328160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced sensitization to taxol-induced apoptosis by herceptin pretreatment in ErbB2-overexpressing breast cancer cells.
    Lee S; Yang W; Lan KH; Sellappan S; Klos K; Hortobagyi G; Hung MC; Yu D
    Cancer Res; 2002 Oct; 62(20):5703-10. PubMed ID: 12384528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Supra-additive antitumor effect of sunitinib malate (SU11248, Sutent) combined with docetaxel. A new therapeutic perspective in hormone refractory prostate cancer.
    Guérin O; Formento P; Lo Nigro C; Hofman P; Fischel JL; Etienne-Grimaldi MC; Merlano M; Ferrero JM; Milano G
    J Cancer Res Clin Oncol; 2008 Jan; 134(1):51-7. PubMed ID: 17593391
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined trastuzumab and paclitaxel treatment better inhibits ErbB-2-mediated angiogenesis in breast carcinoma through a more effective inhibition of Akt than either treatment alone.
    Klos KS; Zhou X; Lee S; Zhang L; Yang W; Nagata Y; Yu D
    Cancer; 2003 Oct; 98(7):1377-85. PubMed ID: 14508823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cooperative inhibitory effect of novel mixed backbone oligonucleotide targeting protein kinase A in combination with docetaxel and anti-epidermal growth factor-receptor antibody on human breast cancer cell growth.
    Tortora G; Caputo R; Pomatico G; Pepe S; Bianco AR; Agrawal S; Mendelsohn J; Ciardiello F
    Clin Cancer Res; 1999 Apr; 5(4):875-81. PubMed ID: 10213224
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bevacizumab for the first-line treatment of human epidermal growth factor receptor 2-negative advanced breast cancer.
    Damasceno M
    Curr Opin Oncol; 2011 Apr; 23 Suppl():S3-9. PubMed ID: 21490481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual targeting of Bcl-2 and VEGF: a potential strategy to improve therapy for prostate cancer.
    Anai S; Sakamoto N; Sakai Y; Tanaka M; Porvasnik S; Urbanek C; Cao W; Goodison S; Rosser CJ
    Urol Oncol; 2011; 29(4):421-9. PubMed ID: 19576799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.